Bartsch Y, Webb N, Burgess E, Kang J, Lauffenburger D, Julg B
MAbs. 2025; 17(1):2465391.
PMID: 39950649
PMC: 11834420.
DOI: 10.1080/19420862.2025.2465391.
Kwak H, Choi G, Kim S, Park J, Kwon Y, Lee Y
Sci Rep. 2025; 15(1):1613.
PMID: 39794345
PMC: 11723924.
DOI: 10.1038/s41598-024-80674-x.
Slein M, Backes I, Kelkar N, Garland C, Khanwalkar U, Sholukh A
bioRxiv. 2024; .
PMID: 39605495
PMC: 11601663.
DOI: 10.1101/2024.11.20.624598.
Araki K, Maeda R
Antibodies (Basel). 2024; 13(4).
PMID: 39584990
PMC: 11587137.
DOI: 10.3390/antib13040090.
Lefranc M, Lefranc G
Immunol Rev. 2024; 328(1):473-506.
PMID: 39367563
PMC: 11659927.
DOI: 10.1111/imr.13399.
Analysis of Beyfortus (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention.
Banoun H
Curr Issues Mol Biol. 2024; 46(9):10369-10395.
PMID: 39329969
PMC: 11431526.
DOI: 10.3390/cimb46090617.
TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma.
Li Q, Zhang K, Yu Y, Yu Z, Xu J, Shen W
PLoS One. 2024; 19(9):e0310889.
PMID: 39321199
PMC: 11423992.
DOI: 10.1371/journal.pone.0310889.
Reduction of circulating IgE and allergens by a pH-sensitive antibody with enhanced FcγRIIb binding.
Li N, Gong N, Duan B, Zhang Y, Jian Y, Xu Y
Mol Ther. 2024; 32(10):3729-3742.
PMID: 39228125
PMC: 11489548.
DOI: 10.1016/j.ymthe.2024.08.029.
evaluation of the role of Fab glycosylation in cetuximab antibody dynamics.
Saporiti S, Bianchi D, Ben Mariem O, Rossi M, Guerrini U, Eberini I
Front Immunol. 2024; 15:1429600.
PMID: 39185413
PMC: 11342397.
DOI: 10.3389/fimmu.2024.1429600.
Modulation of the pharmacokinetics of soluble ACE2 decoy receptors through glycosylation.
Skeeters S, Bagale K, Stepanyuk G, Thieker D, Aguhob A, Chan K
Mol Ther Methods Clin Dev. 2024; 32(3):101301.
PMID: 39185275
PMC: 11342882.
DOI: 10.1016/j.omtm.2024.101301.
Fc-engineered antibodies promote neutrophil-dependent control of Mycobacterium tuberculosis.
Irvine E, Nikolov A, Khan M, Peters J, Lu R, Sixsmith J
Nat Microbiol. 2024; 9(9):2369-2382.
PMID: 39174703
PMC: 11371646.
DOI: 10.1038/s41564-024-01777-9.
ENPP1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia.
Reichenberger E, OBrien K, Hatori A, Carpenter T, van de Wetering K, Flaman L
JBMR Plus. 2024; 8(9):ziae103.
PMID: 39165910
PMC: 11334334.
DOI: 10.1093/jbmrpl/ziae103.
Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling.
Tulika T, Ruso-Julve F, Ahmadi S, Ljungars A, Rivera-de-Torre E, Wade J
Structure. 2024; 32(9):1404-1418.e7.
PMID: 39146931
PMC: 11385703.
DOI: 10.1016/j.str.2024.07.014.
Rapid depletion of "catch-and-release" anti-ASGR1 antibody in vivo.
Devanaboyina S, Li P, LaGory E, Poon-Andersen C, Cook K, Soto M
MAbs. 2024; 16(1):2383013.
PMID: 39051531
PMC: 11275528.
DOI: 10.1080/19420862.2024.2383013.
Modulation of the high concentration viscosity of IgG antibodies using clinically validated Fc mutations.
Heisler J, Kovner D, Izadi S, Zarzar J, Carter P
MAbs. 2024; 16(1):2379560.
PMID: 39028186
PMC: 11262234.
DOI: 10.1080/19420862.2024.2379560.
Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity.
Khaimraj A, Baehr C, Hicks D, Raleigh M, Pravetoni M
J Immunol. 2024; 213(5):663-668.
PMID: 39018496
PMC: 11333160.
DOI: 10.4049/jimmunol.2400170.
Inhibition of Vascular Smooth Muscle Cell Proliferation by ENPP1: The Role of CD73 and the Adenosine Signaling Axis.
Tchernychev B, Nitschke Y, Chu D, Sullivan C, Flaman L, OBrien K
Cells. 2024; 13(13.
PMID: 38994980
PMC: 11240470.
DOI: 10.3390/cells13131128.
Insight into the avidity-affinity relationship of the bivalent, pH-dependent interaction between IgG and FcRn.
Reusch J, Andersen J, Rant U, Schlothauer T
MAbs. 2024; 16(1):2361585.
PMID: 38849969
PMC: 11164218.
DOI: 10.1080/19420862.2024.2361585.
In vivo neutralization of coral snake venoms with an oligoclonal nanobody mixture in a murine challenge model.
Benard-Valle M, Wouters Y, Ljungars A, Nguyen G, Ahmadi S, Ebersole T
Nat Commun. 2024; 15(1):4310.
PMID: 38773068
PMC: 11109316.
DOI: 10.1038/s41467-024-48539-z.
Ultrapotent Broadly Neutralizing Human-llama Bispecific Antibodies against HIV-1.
Xu J, Zhou T, McKee K, Zhang B, Liu C, Nazzari A
Adv Sci (Weinh). 2024; 11(26):e2309268.
PMID: 38704686
PMC: 11234422.
DOI: 10.1002/advs.202309268.